Heart failure affects more than 2 million Americans, and about 400,000 new cases are diagnosed each year.
The direct economic cost is over $10 billion/year.
About 75% of this cost is spent on hospitalization, and almost 20% on nursing home care.
Drugs such as angiotensin-converting enzyme (ACE) inhibitors reduce mortality and hospitalization and are thus very cost effective in the management of heart failure.
Cost-effective strategies should focus on keeping patients out of the hospital.
Additional savings can be obtained by more appropriate utilization of tests.
Mots-clés Pascal : Insuffisance cardiaque, Hospitalisation, Analyse coût efficacité, Economie santé, Inhibiteur enzyme, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Proteinases, Hydrolases, Enzyme, Chimiothérapie, Traitement, Homme, Vasodilatateur, Appareil circulatoire pathologie, Cardiopathie, Angiotensin converting enzyme
Mots-clés Pascal anglais : Heart failure, Hospitalization, Cost efficiency analysis, Health economy, Enzyme inhibitor, Peptidyl-dipeptidase A, Peptidyl-dipeptidases, Proteinases, Hydrolases, Enzyme, Chemotherapy, Treatment, Human, Vasodilator agent, Cardiovascular disease, Heart disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0181964
Code Inist : 002B12A01. Création : 199608.